ABC – X
11 Apr 2022
Trial Summary
This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.
Acronym:
ABC-X
ACTRN/NCT /ethics:
NCT03340129
Scientific title:
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X)
Sponsor / Cooperative group:
Melanoma Institute Australia
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2019-08-14 |
| Anticipated End Date | 2025-08-01 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |